|
1.
|
Whalen GF, Sullivan M, Piperdi B, Wasseff W, Galili U. Cancer Immunotherapy by Intratumoral Injection of a-gal Glycolipids. Anticancer Res. 2012 Sep; 32(9):3861-8.
|
|
|
|
|
2.
|
Hurwitz ZM, Ignotz R, Lalikos JF, Galili U. Accelerated Porcine Wound Healing after Treatment with a-Gal Nanoparticles. Plast Reconstr Surg. 2012 Feb; 129(2):242e-51e.
|
|
|
|
|
3.
|
Galili U. Induced anti-non gal antibodies in human xenograft recipients. Transplantation. 2012 Jan 15; 93(1):11-6.
|
|
|
|
|
4.
|
Galili U. Conversion of Tumors into Autologous Vaccines by Intratumoral Injection of a-Gal Glycolipids that Induce Anti-Gal/a-Gal Epitope Interaction. Clin Dev Immunol. 2011; 2011:134020.
|
|
|
|
|
5.
|
Wigglesworth KM, Racki WJ, Mishra R, Szomolanyi-Tsuda E, Greiner DL, Galili U. Rapid Recruitment and Activation of Macrophages by Anti-Gal/{alpha}-Gal Liposome Interaction Accelerates Wound Healing. J Immunol. 2011 Apr 1; 186(7):4422-32.
|
|
|
|
|
6.
|
Abdel-Motal UM, Wang S, Awad A, Lu S, Wigglesworth K, Galili U. Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing alpha-gal epitopes. Vaccine. 2010 Feb 17; 28(7):1758-65.
|
|
|
|
|
7.
|
Galili U, Wigglesworth K, Abdel-Motal UM. Accelerated healing of skin burns by anti-Gal/alpha-gal liposomes interaction. Burns. 2010 Mar; 36(2):239-51.
|
|
|
|
|
8.
|
Abdel-Motal UM, Wigglesworth K, Galili U. Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody. Vaccine. 2009 May 18; 27(23):3072-82.
|
|
|
|
|
9.
|
Abdel-Motal UM, Wigglesworth K, Galili U. Intratumoral injection of alpha-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity. Cancer Immunol Immunother. 2009 Oct; 58(10):1545-56.
|
|
|
|
|
10.
|
Macher BA, Galili U. The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochim Biophys Acta. 2008 Feb; 1780(2):75-88.
|
|
|
|
|
11.
|
Abdel-Motal UM, Guay HM, Wigglesworth K, Welsh RM, Galili U. Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells. J Virol. 2007 Sep; 81(17):9131-41.
|
|
|
|
|
12.
|
Galili U, Wigglesworth K, Abdel-Motal UM. Intratumoral injection of alpha-gal glycolipids induces xenograft-like destruction and conversion of lesions into endogenous vaccines. J Immunol. 2007 Apr 1; 178(7):4676-87.
|
|
|
|
|
13.
|
Stone KR, Walgenbach AW, Turek TJ, Somers DL, Wicomb W, Galili U. Anterior cruciate ligament reconstruction with a porcine xenograft: a serologic, histologic, and biomechanical study in primates. Arthroscopy. 2007 Apr; 23(4):411-9.
|
|
|
|
|
14.
|
Stone KR, Abdel-Motal UM, Walgenbach AW, Turek TJ, Galili U. Replacement of human anterior cruciate ligaments with pig ligaments: a model for anti-non-gal antibody response in long-term xenotransplantation. Transplantation. 2007 Jan 27; 83(2):211-9.
|
|
|
|
|
15.
|
Ogawa H, Galili U. Profiling terminal N-acetyllactosamines of glycans on mammalian cells by an immuno-enzymatic assay. Glycoconj J. 2006 Dec; 23(9):663-74.
|
|
|
|
|
16.
|
Galili U. Xenotransplantation and ABO incompatible transplantation: the similarities they share. Transfus Apher Sci. 2006 Aug; 35(1):45-58.
|
|
|
|
|
17.
|
Abdel-Motal U, Wang S, Lu S, Wigglesworth K, Galili U. Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes. J Virol. 2006 Jul; 80(14):6943-51.
|
|
|
|
|
18.
|
Galili U. The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. Immunol Cell Biol. 2005 Dec; 83(6):674-86.
|
|
|
|
|
19.
|
Deriy L, Ogawa H, Gao GP, Galili U. In vivo targeting of vaccinating tumor cells to antigen-presenting cells by a gene therapy method with adenovirus containing the alpha1,3galactosyltransferase gene. Cancer Gene Ther. 2005 Jun; 12(6):528-39.
|
|
|
|
|
20.
|
Manches O, Plumas J, Lui G, Chaperot L, Molens JP, Sotto JJ, Bensa JC, Galili U. Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells. Haematologica. 2005 May; 90(5):625-34.
|
|
|
|
|
21.
|
Galili U. Immune response, accommodation, and tolerance to transplantation carbohydrate antigens. Transplantation. 2004 Oct 27; 78(8):1093-8.
|
|
|
|
|
22.
|
Kirchhof N, Shibata S, Wijkstrom M, Kulick DM, Salerno CT, Clemmings SM, Heremans Y, Galili U, Sutherland DE, Dalmasso AP, Hering BJ. Reversal of diabetes in non-immunosuppressed rhesus macaques by intraportal porcine islet xenografts precedes acute cellular rejection. Xenotransplantation. 2004 Sep; 11(5):396-407.
|
|
|
|
|
23.
|
Galili U. Autologous tumor vaccines processed to express alpha-gal epitopes: a practical approach to immunotherapy in cancer. Cancer Immunol Immunother. 2004 Nov; 53(11):935-45.
|
|
|
|
|
24.
|
Leventhal JR, Sun J, Zhang J, Galili U, Chong A, Baker M, Kaufman DB, Wright JR. Evidence that tilapia islets do not express alpha-(1,3)gal: implications for islet xenotransplantation. Xenotransplantation. 2004 May; 11(3):276-83.
|
|
|
|
|
25.
|
Ogawa H, Mohiuddin MM, Yin DP, Shen J, Chong AS, Galili U. Mouse-heart grafts expressing an incompatible carbohydrate antigen. II. Transition from accommodation to tolerance. Transplantation. 2004 Feb 15; 77(3):366-73.
|
|
|
|
|
26.
|
Ogawa H, Yin DP, Galili U. Induction of immune tolerance to a transplantation carbohydrate antigen by gene therapy with autologous lymphocytes transduced with adenovirus containing the corresponding glycosyltransferase gene. Gene Ther. 2004 Feb; 11(3):292-301.
|
|
|
|
|
27.
|
Galili U, Chen ZC, DeGeest K. Expression of alpha-gal epitopes on ovarian carcinoma membranes to be used as a novel autologous tumor vaccine. Gynecol Oncol. 2003 Jul; 90(1):100-8.
|
|
|
|
|
28.
|
Mohiuddin MM, Ogawa H, Yin DP, Galili U. Tolerance induction to a mammalian blood group-like carbohydrate antigen by syngeneic lymphocytes expressing the antigen, II: tolerance induction on memory B cells. Blood. 2003 Jul 1; 102(1):229-36.
|
|
|
|
|
29.
|
Mohiuddin MM, Ogawa H, Yin DP, Shen J, Galili U. Antibody-mediated accommodation of heart grafts expressing an incompatible carbohydrate antigen. Transplantation. 2003 Feb 15; 75(3):258-62.
|
|
|
|
|
30.
|
Galili U, Ishida H, Tanabe K, Toma H. Anti-gal A/B, a novel anti-blood group antibody identified in recipients of abo-incompatible kidney allografts. Transplantation. 2002 Dec 15; 74(11):1574-80.
|
|
|
|
|
31.
|
Tanemura M, Chong AS, DiSesa VJ, Galili U. Direct killing of xenograft cells by CD8+ T cells of discordant xenograft recipients. Transplantation. 2002 Dec 15; 74(11):1587-95.
|
|
|
|
|
32.
|
Ogawa H, Yin DP, Shen J, Galili U. Tolerance induction to a mammalian blood group-like carbohydrate antigen by syngeneic lymphocytes expressing the antigen. Blood. 2003 Mar 15; 101(6):2318-20.
|
|
|
|
|
33.
|
Tanemura M, Ogawa H, Yin DP, Chen ZC, DiSesa VJ, Galili U. Elimination of anti-Gal B cells by alpha-Gal ricin1. Transplantation. 2002 Jun 27; 73(12):1859-68.
|
|
|
|
|
34.
|
Deriy L, Chen ZC, Gao GP, Galili U. Expression of alpha-gal epitopes on HeLa cells transduced with adenovirus containing alpha1,3galactosyltransferase cDNA. Glycobiology. 2002 Feb; 12(2):135-44.
|
|
|
|
|
35.
|
Galili U, Chen ZC, Manches O, Plumas J, Preisler H. Preparation of autologous leukemia and lymphoma vaccines expressing alpha-gal epitopes. J Hematother Stem Cell Res. 2001 Aug; 10(4):501-11.
|
|
|
|
|
36.
|
Galili U. The alpha-gal epitope (Gal alpha 1-3Gal beta 1-4GlcNAc-R) in xenotransplantation. Biochimie. 2001 Jul; 83(7):557-63.
|
|
|
|
|
37.
|
Chen ZC, Tanemura M, Galili U. Synthesis of alpha-gal epitopes (Galalpha1-3Galbeta1-4GlcNAc-R) on human tumor cells by recombinant alpha1,3galactosyltransferase produced in Pichia pastoris. Glycobiology. 2001 Jul; 11(7):577-86.
|
|
|
|
|
38.
|
Galili U. The nature of elicited xenoantibodies. Transplant Proc. 2001 Feb-Mar; 33(1-2):688-9.
|
|
|
|
|
39.
|
Tanemura M, Yin D, DiSesa VJ, Galili U. Preventing anti-Gal response in xenograft recipients by an alpha-Gal toxin. Transplant Proc. 2001 Feb-Mar; 33(1-2):699-700.
|
|
|
|
|
40.
|
Gorelik E, Galili U, Raz A. On the role of cell surface carbohydrates and their binding proteins (lectins) in tumor metastasis. Cancer Metastasis Rev. 2001; 20(3-4):245-77.
|
|
|
|
|
41.
|
Tanemura M, Galili U. Differential expression of alpha-Gal epitopes on pig and mouse organs. Transplant Proc. 2000 Aug; 32(5):843.
|
|
|
|
|
42.
|
Chen ZC, Galili U. Genes coding for anti-Gal in knock-out mice for the alpha1, 3Galactosyltransferase gene: analysis by hybridomas. Transplant Proc. 2000 Aug; 32(5):846-7.
|
|
|
|
|
43.
|
Tanemura M, Galili U. Identification of B cells with receptors for alpha-Gal epitopes (Galalpha 1-3Galbeta1-4GlcNac-R) in xenograft recipients. Transplant Proc. 2000 Aug; 32(5):857-8.
|
|
|
|
|
44.
|
Tanemura M, Galili U. T cells interacting with the alpha-Gal epitope: studies in alpha1, 3Galactosyltransferase knock-out mice. Transplant Proc. 2000 Aug; 32(5):921-3.
|
|
|
|
|
45.
|
Tanemura M, Yin D, Chong A, Galili U. Differential immune response to carbohydrate epitopes on allo- and xenografts: implications for accommodation. Transplant Proc. 2000 Aug; 32(5):991-3.
|
|
|
|
|
46.
|
Chen ZC, Radic MZ, Galili U. Genes coding evolutionary novel anti-carbohydrate antibodies: studies on anti-Gal production in alpha 1,3galactosyltransferase knock out mice. Mol Immunol. 2000 Jun; 37(8):455-66.
|
|
|
|
|
47.
|
Maruyama S, Cantu E, Galili U, D'Agati V, Godman G, Stern DM, Andres G. alpha-galactosyl epitopes on glycoproteins of porcine renal extracellular matrix. Kidney Int. 2000 Feb; 57(2):655-63.
|
|
|
|
|
48.
|
Tanemura M, Yin D, Chong AS, Galili U. Differential immune responses to alpha-gal epitopes on xenografts and allografts: implications for accommodation in xenotransplantation. J Clin Invest. 2000 Feb; 105(3):301-10.
|
|
|
|
|
49.
|
Tanemura M, Maruyama S, Galili U. Differential expression of alpha-GAL epitopes (Galalpha1-3Galbeta1-4GlcNAc-R) on pig and mouse organs. Transplantation. 2000 Jan 15; 69(1):187-90.
|
|
|
|
|
50.
|
Maruyama S, Cantu E, DeMartino C, Wang CY, Chen J, Al-Mohanna F, Nakeeb SM, D'Agati V, Pernis B, Galili U, Godman G, Stern DM, Andres G. Interaction of baboon anti-alpha-galactosyl antibody with pig tissues. Am J Pathol. 1999 Nov; 155(5):1635-49.
|
|
|
|
|
51.
|
LaTemple DC, Abrams JT, Zhang SY, Galili U. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase. Cancer Res. 1999 Jul 15; 59(14):3417-23.
|
|
|
|
|
52.
|
Maruyama S, Cantu E3rd , Pernis B, Galili U, Godman G, Stern DM, Andres G. Alpha-galactosyl antibody redistributes alpha-galactosyl at the surface of pig blood and endothelial cells. Transpl Immunol. 1999 Jun; 7(2):101-6.
|
|
|
|
|
53.
|
Galili U. Significance of anti-Gal IgG in chronic xenograft rejection. Transplant Proc. 1999 Feb-Mar; 31(1-2):940-1.
|
|
|
|
|
54.
|
Galili U. Evolution of alpha 1,3galactosyltransferase and of the alpha-Gal epitope. Subcell Biochem. 1999; 32:1-23.
|
|
|
|
|
55.
|
Henion TR, Galili U. Structure function studies of a New World monkey alpha 1,3galactosyltransferase. Analysis of alternative splicing and expression in baculovirus system. Subcell Biochem. 1999; 32:49-77.
|
|
|
|
|
56.
|
Galili U, Wang L, LaTemple DC, Radic MZ. The natural anti-Gal antibody. Subcell Biochem. 1999; 32:79-106.
|
|
|
|
|
57.
|
Rother RP, Galili U. alpha-Gal epitopes on viral glycoproteins. Subcell Biochem. 1999; 32:143-72.
|
|
|
|
|
58.
|
Galili U. Graves' disease as a model for anti-Gal involvement in autoimmune diseases. Subcell Biochem. 1999; 32:339-60.
|
|
|
|
|
59.
|
LaTemple DC, Galili U. Enhancement of autologous tumor vaccine immunogenicity by anti-Gal. Subcell Biochem. 1999; 32:361-79.
|
|
|
|
|
60.
|
LaTemple DC, Galili U. Adult and neonatal anti-Gal response in knock-out mice for alpha1,3galactosyltransferase. Xenotransplantation. 1998 Aug; 5(3):191-6.
|
|
|
|
|
61.
|
Stone KR, Ayala G, Goldstein J, Hurst R, Walgenbach A, Galili U. Porcine cartilage transplants in the cynomolgus monkey. III. Transplantation of alpha-galactosidase-treated porcine cartilage. Transplantation. 1998 Jun 27; 65(12):1577-83.
|
|
|
|
|
62.
|
Gregory CR, Galili U, Hancock WW, Valverde CR, Griffey SM, Berryman ER, Morris RE. Squirrel monkeys hyperacutely reject porcine musculocutaneous flaps despite a lack of naturally occurring xenoantibodies. Transplant Proc. 1998 Jun; 30(4):1082-3.
|
|
|
|
|
63.
|
Minanov OP, Artrip JH, Szabolcs M, Kwiatkowski PA, Galili U, Itescu S, Michler RE. Triple immunosuppression reduces mononuclear cell infiltration and prolongs graft life in pig-to-newborn baboon cardiac xenotransplantation. J Thorac Cardiovasc Surg. 1998 May; 115(5):998-1006.
|
|
|
|
|
64.
|
Galili U, LaTemple DC, Radic MZ. A sensitive assay for measuring alpha-Gal epitope expression on cells by a monoclonal anti-Gal antibody. Transplantation. 1998 Apr 27; 65(8):1129-32.
|
|
|
|
|
65.
|
Palmetshofer A, Galili U, Dalmasso AP, Robson SC, Bach FH. Alpha-galactosyl epitope-mediated activation of porcine aortic endothelial cells: type II activation. Transplantation. 1998 Apr 15; 65(7):971-8.
|
|
|
|
|
66.
|
Palmetshofer A, Galili U, Dalmasso AP, Robson SC, Bach FH. Alpha-galactosyl epitope-mediated activation of porcine aortic endothelial cells: type I activation. Transplantation. 1998 Mar 27; 65(6):844-53.
|
|
|
|
|
67.
|
Henion TR, Gerhard W, Anaraki F, Galili U. Synthesis of alpha-gal epitopes on influenza virus vaccines, by recombinant alpha 1,3galactosyltransferase, enables the formation of immune complexes with the natural anti-Gal antibody. Vaccine. 1997 Aug; 15(11):1174-82.
|
|
|
|
|
68.
|
Shinkel TA, Chen CG, Salvaris E, Henion TR, Barlow H, Galili U, Pearse MJ, d'Apice AJ. Changes in cell surface glycosylation in alpha1,3-galactosyltransferase knockout and alpha1,2-fucosyltransferase transgenic mice. Transplantation. 1997 Jul 27; 64(2):197-204.
|
|
|
|
|
69.
|
Galili U, LaTemple DC. Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Immunol Today. 1997 Jun; 18(6):281-5.
|
|
|
|
|
70.
|
Wang L, Radic MZ, Siegel D, Chang T, Bracy J, Galili U. Cloning of anti-Gal Fabs from combinatorial phage display libraries: structural analysis and comparison of Fab expression in pComb3H and pComb8 phage. Mol Immunol. 1997 Jun; 34(8-9):609-18.
|
|
|
|
|
71.
|
Stone KR, Walgenbach AW, Abrams JT, Nelson J, Gillett N, Galili U. Porcine and bovine cartilage transplants in cynomolgus monkey: I. A model for chronic xenograft rejection. Transplantation. 1997 Mar 15; 63(5):640-5.
|
|
|
|
|
72.
|
Galili U, LaTemple DC, Walgenbach AW, Stone KR. Porcine and bovine cartilage transplants in cynomolgus monkey: II. Changes in anti-Gal response during chronic rejection. Transplantation. 1997 Mar 15; 63(5):646-51.
|
|
|
|
|
73.
|
Gorelik E, Xu F, Henion T, Anaraki F, Galili U. Reduction of metastatic properties of BL6 melanoma cells expressing terminal fucose(alpha)1-2-galactose after alpha1,2-fucosyltransferase cDNA transfection. Cancer Res. 1997 Jan 15; 57(2):332-6.
|
|
|
|
|
74.
|
Teneberg S, Lönnroth I, Torres López JF, Galili U, Halvarsson MO, Angström J, Karlsson KA. Molecular mimicry in the recognition of glycosphingolipids by Gal alpha 3 Gal beta 4 GlcNAc beta-binding Clostridium difficile toxin A, human natural anti alpha-galactosyl IgG and the monoclonal antibody Gal-13: characterization of a binding-active human glycosphingolipid, non-identical with the animal receptor. Glycobiology. 1996 Sep; 6(6):599-609.
|
|
|
|
|
75.
|
Galili U, Matta KL. Inhibition of anti-Gal IgG binding to porcine endothelial cells by synthetic oligosaccharides. Transplantation. 1996 Jul 27; 62(2):256-62.
|
|
|
|
|
76.
|
LaTemple DC, Henion TR, Anaraki F, Galili U. Synthesis of alpha-galactosyl epitopes by recombinant alpha1,3galactosyl transferase for opsonization of human tumor cell vaccines by anti-galactose. Cancer Res. 1996 Jul 1; 56(13):3069-74.
|
|
|
|
|
77.
|
Pothoulakis C, Galili U, Castagliuolo I, Kelly CP, Nikulasson S, Dudeja PK, Brasitus TA, LaMont JT. A human antibody binds to alpha-galactose receptors and mimics the effects of Clostridium difficile toxin A in rat colon. Gastroenterology. 1996 Jun; 110(6):1704-12.
|
|
|
|
|
78.
|
Galili U, Tibell A, Samuelsson B, Rydberg L, Groth CG. Increased anti-Gal activity in diabetic patients transplanted with porcine islet cells. Transplant Proc. 1996 Apr; 28(2):564-6.
|
|
|
|
|
79.
|
Galili U, Gregory CR, Morris RE. New World monkeys as a primate model for xenografts in the absence of anti-Gal. Transplant Proc. 1996 Apr; 28(2):567-8.
|
|
|
|
|
80.
|
Galili U, Repik PM, Anaraki F, Mozdzanowska K, Washko G, Gerhard W. Enhancement of antigen presentation of influenza virus hemagglutinin by the natural human anti-Gal antibody. Vaccine. 1996 Mar; 14(4):321-8.
|
|
|
|
|
81.
|
Galili U, Anaraki F. alpha-galactosyl (Galalpha1-3Galbeta1-4GlcNAc-R) epitopes on human cells: synthesis of the epitope on human red cells by recombinant primate alpha1,3galactosyltransferase expressed in E.coli. Glycobiology. 1995 Dec; 5(8):775-82.
|
|
|
|
|
82.
|
Gorelik E, Duty L, Anaraki F, Galili U. Alterations of cell surface carbohydrates and inhibition of metastatic property of murine melanomas by alpha 1,3 galactosyltransferase gene transfection. Cancer Res. 1995 Sep 15; 55(18):4168-73.
|
|
|
|
|
83.
|
Wang L, Radic MZ, Galili U. Human anti-Gal heavy chain genes. Preferential use of VH3 and the presence of somatic mutations. J Immunol. 1995 Aug 1; 155(3):1276-85.
|
|
|
|
|
84.
|
Galili U, Gregory CR, Morris RE. Contribution of anti-Gal to primate and human IgG binding to porcine endothelial cells. Transplantation. 1995 Jul 27; 60(2):210-3.
|
|
|
|
|
85.
|
Wang L, Anaraki F, Henion TR, Galili U. Variations in activity of the human natural anti-Gal antibody in young and elderly populations. J Gerontol A Biol Sci Med Sci. 1995 Jul; 50(4):M227-33.
|
|
|
|
|
86.
|
Galili U, Tibell A, Samuelsson B, Rydberg L, Groth CG. Increased anti-Gal activity in diabetic patients transplanted with fetal porcine islet cell clusters. Transplantation. 1995 Jun 15; 59(11):1549-56.
|
|
|
|
|
87.
|
Hamadeh RM, Galili U, Zhou P, Griffiss JM. Anti-alpha-galactosyl immunoglobulin A (IgA), IgG, and IgM in human secretions. Clin Diagn Lab Immunol. 1995 Mar; 2(2):125-31.
|
|
|
|
|
88.
|
Winand RJ, Devigne JW, Meurisse M, Galili U. Specific stimulation of Graves' disease thyrocytes by the natural anti-Gal antibody from normal and autologous serum. J Immunol. 1994 Aug 1; 153(3):1386-95.
|
|
|
|
|
89.
|
Repik PM, Strizki JM, Galili U. Differential host-dependent expression of alpha-galactosyl epitopes on viral glycoproteins: a study of eastern equine encephalitis virus as a model. J Gen Virol. 1994 May; 75 ( Pt 5):1177-81.
|
|
|
|
|
90.
|
Henion TR, Macher BA, Anaraki F, Galili U. Defining the minimal size of catalytically active primate alpha 1,3 galactosyltransferase: structure-function studies on the recombinant truncated enzyme. Glycobiology. 1994 Apr; 4(2):193-201.
|
|
|
|
|
91.
|
Gorelik E, Kim M, Duty L, Henion T, Galili U. Control of metastatic properties of BL6 melanoma cells by H-2Kb gene: immunological and nonimmunological mechanisms. Clin Exp Metastasis. 1993 Nov; 11(6):439-52.
|
|
|
|
|
92.
|
Galili U, Anaraki F, Thall A, Hill-Black C, Radic M. One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. Blood. 1993 Oct 15; 82(8):2485-93.
|
|
|
|
|
93.
|
Galili U. Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunol Today. 1993 Oct; 14(10):480-2.
|
|
|
|
|
94.
|
Kim M, Rao MV, Tweardy DJ, Prakash M, Galili U, Gorelik E. Lectin-induced apoptosis of tumour cells. Glycobiology. 1993 Oct; 3(5):447-53.
|
|
|
|
|
95.
|
Winand RJ, Anaraki F, Etienne-Decerf J, Galili U. Xenogeneic thyroid-stimulating hormone-like activity of the human natural anti-Gal antibody. Interaction of anti-Gal with porcine thyrocytes and with recombinant human thyroid-stimulating hormone receptors expressed on mouse cells. J Immunol. 1993 Oct 1; 151(7):3923-34.
|
|
|
|
|
96.
|
Galili U. Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG (anti-Gal) antibody. Springer Semin Immunopathol. 1993; 15(2-3):155-71.
|
|
|
|
|
97.
|
Heda GD, Henion TR, Galili U. A simple in vitro site directed mutagenesis of concatamerized cDNA by inverse polymerase chain reaction. Nucleic Acids Res. 1992 Oct 11; 20(19):5241-2.
|
|
|
|
|
98.
|
Galili U, Ron M, Sharon R. The natural anti-alpha-galactosyl IgG in seminal fluid. A simple means to determine damage to the blood-genital tract barrier in infertile males. J Immunol Methods. 1992 Jul 6; 151(1-2):117-22.
|
|
|
|
|
99.
|
Hamadeh RM, Jarvis GA, Galili U, Mandrell RE, Zhou P, Griffiss JM. Human natural anti-Gal IgG regulates alternative complement pathway activation on bacterial surfaces. J Clin Invest. 1992 Apr; 89(4):1223-35.
|
|
|
|
|
100.
|
Galili U, Swanson K. Gene sequences suggest inactivation of alpha-1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys. Proc Natl Acad Sci U S A. 1991 Aug 15; 88(16):7401-4.
|
|
|
|
|
101.
|
Thall A, Etienne-Decerf J, Winand RJ, Galili U. The alpha-galactosyl epitope on mammalian thyroid cells. Acta Endocrinol (Copenh). 1991 Jun; 124(6):692-9.
|
|
|
|
|
102.
|
Sorette MP, Galili U, Clark MR. Comparison of serum anti-band 3 and anti-Gal antibody binding to density-separated human red blood cells. Blood. 1991 Feb 1; 77(3):628-36.
|
|
|
|
|
103.
|
Galili U. The natural anti-Gal antibody: evolution and autoimmunity in man. Immunol Ser. 1991; 55:355-73.
|
|
|
|
|
104.
|
Thall A, Etienne-Decerf J, Winand RJ, Galili U. The alpha-galactosyl epitope on human normal and autoimmune thyroid cells. Autoimmunity. 1991; 10(2):81-7.
|
|
|
|
|
105.
|
Thall A, Galili U. Distribution of Gal alpha 1----3Gal beta 1----4GlcNAc residues on secreted mammalian glycoproteins (thyroglobulin, fibrinogen, and immunoglobulin G) as measured by a sensitive solid-phase radioimmunoassay. Biochemistry. 1990 Apr 24; 29(16):3959-65.
|
|
|
|
|
106.
|
Galili U. Abnormal expression of alpha-galactosyl epitopes in man. A trigger for autoimmune processes? Lancet. 1989 Aug 12; 2(8659):358-61.
|
|
|
|
|
107.
|
Avila JL, Rojas M, Galili U. Immunogenic Gal alpha 1----3Gal carbohydrate epitopes are present on pathogenic American Trypanosoma and Leishmania. J Immunol. 1989 Apr 15; 142(8):2828-34.
|
|
|
|
|
108.
|
Galili U, Macher BA. Interaction between anti-Gal and human tumor cells: a natural defense mechanism? J Natl Cancer Inst. 1989 Feb 1; 81(3):178-9.
|
|
|
|
|
109.
|
Galili U, Kobrin E, Macher BA, Shohet SB. Anti-Gal and human red cell aging. Prog Clin Biol Res. 1989; 319:225-41; discussion 242-5.
|
|
|
|
|
110.
|
Galili U, Shohet SB, Kobrin E, Stults CL, Macher BA. Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J Biol Chem. 1988 Nov 25; 263(33):17755-62.
|
|
|
|
|
111.
|
Galili U, Mandrell RE, Hamadeh RM, Shohet SB, Griffiss JM. Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun. 1988 Jul; 56(7):1730-7.
|
|
|
|
|
112.
|
Galili U. The two antibody specificities within human anti-blood group B antibodies. Transfus Med Rev. 1988 Jun; 2(2):112-21.
|
|
|
|
|
113.
|
Lane PA, Galili U, Iarocci TA, Shew RL, Mentzer WC. Cellular dehydration and immunoglobulin binding in senescent neonatal erythrocytes. Pediatr Res. 1988 Mar; 23(3):288-92.
|
|
|
|
|
114.
|
Galili U. Glucocorticoid-induced lysis of human leukemia cells. Prog Clin Biol Res. 1988; 276:43-59.
|
|
|
|
|
115.
|
Galili U. The natural anti-Gal antibody, the B-like antigen, and human red cell aging. Blood Cells. 1988; 14(1):205-28.
|
|
|
|
|
116.
|
Buehler J, Galili U, Macher BA. Use of the enzyme-linked immunoadsorbent assay to monitor the purification of glycosphingolipid antigens by high-performance liquid chromatography. Anal Biochem. 1987 Aug 1; 164(2):521-5.
|
|
|
|
|
117.
|
Galili U, Basbaum CB, Shohet SB, Buehler J, Macher BA. Identification of erythrocyte Gal alpha 1-3Gal glycosphingolipids with a mouse monoclonal antibody, Gal-13. J Biol Chem. 1987 Apr 5; 262(10):4683-8.
|
|
|
|
|
118.
|
Galili U, Buehler J, Shohet SB, Macher BA. The human natural anti-Gal IgG. III. The subtlety of immune tolerance in man as demonstrated by crossreactivity between natural anti-Gal and anti-B antibodies. J Exp Med. 1987 Mar 1; 165(3):693-704.
|
|
|
|
|
119.
|
Galili U, Clark MR, Shohet SB, Buehler J, Macher BA. Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha 1----3Gal epitope in primates. Proc Natl Acad Sci U S A. 1987 Mar; 84(5):1369-73.
|
|
|
|
|
120.
|
Galili U, Flechner I, Knyszynski A, Danon D, Rachmilewitz EA. The natural anti-alpha-galactosyl IgG on human normal senescent red blood cells. Br J Haematol. 1986 Feb; 62(2):317-24.
|
|
|
|
|
121.
|
Sharon R, Duke-Cohan JS, Galili U. Determination of ABO blood group zygosity by an antiglobulin rosetting technique and cell-based enzyme immunoassay. Vox Sang. 1986; 50(4):245-9.
|
|
|
|
|
122.
|
Galili U, Clark MR, Shohet SB. Excessive binding of natural anti-alpha-galactosyl immunoglobin G to sickle erythrocytes may contribute to extravascular cell destruction. J Clin Invest. 1986 Jan; 77(1):27-33.
|
|
|
|
|
123.
|
Galili U, Macher BA, Buehler J, Shohet SB. Human natural anti-alpha-galactosyl IgG. II. The specific recognition of alpha (1----3)-linked galactose residues. J Exp Med. 1985 Aug 1; 162(2):573-82.
|
|
|
|
|
124.
|
Rachmilewitz EA, Shinar E, Shalev O, Galili U, Schrier SL. Erythrocyte membrane alterations in beta-thalassaemia. Clin Haematol. 1985 Feb; 14(1):163-82.
|
|
|
|
|
125.
|
Galili U, Clark MR, Shohet SB. Excessive binding of the natural anti-alpha-galactosyl IgG to sickle red cells: enhancement of red cell destruction by a physiological process. Trans Assoc Am Physicians. 1985; 98:158-65.
|
|
|
|
|
126.
|
Galili U, Flechner I, Rachmilewitz EA. A naturally occurring anti-alpha-galactosyl IgG recognizing senescent human red cells. Prog Clin Biol Res. 1985; 195:263-78.
|
|
|
|
|
127.
|
Galili U, Rachmilewitz EA, Peleg A, Flechner I. A unique natural human IgG antibody with anti-alpha-galactosyl specificity. J Exp Med. 1984 Nov 1; 160(5):1519-31.
|
|
|
|
|
128.
|
Galili U, Peleg A, Milner Y, Galili N. Be13, a human T-leukemia cell line highly sensitive to dexamethasone-induced cytolysis. Cancer Res. 1984 Oct; 44(10):4594-601.
|
|
|
|
|
129.
|
Sharon R, Galili U. The rosetting antiglobulin test as a means of determining the D zygosity of human red cells. Vox Sang. 1984; 46(3):175-9.
|
|
|
|
|
130.
|
Galili U. Glucocorticoid induced cytolysis of human normal and malignant lymphocytes. J Steroid Biochem. 1983 Jul; 19(1B):483-90.
|
|
|
|
|
131.
|
Galili U, Korkesh A, Kahane I, Rachmilewitz EA. Demonstration of a natural antigalactosyl IgG antibody on thalassemic red blood cells. Blood. 1983 Jun; 61(6):1258-64.
|
|
|
|
|
132.
|
Granat M, Schenker JG, Mor-Yosef S, Rosenkovitch E, Castellanos RC, Galili U. Effects of dexamethasone on proliferation of autologous fibroblasts and on the immune profile in women undergoing pelvic surgery for infertility. Fertil Steril. 1983 Feb; 39(2):180-6.
|
|
|
|
|
133.
|
Castellanos RC, Leizerovitz R, Kaiser N, Galili N, Polliack A, Korkesh A, Galili U. Prothymocytes in postirradiation regenerating rat thymuses: a model for studying early stages in T cell differentiation. J Immunol. 1983 Jan; 130(1):121-9.
|
|
|
|
|
134.
|
Galili N, Galili U. Glucocorticoid-induced lysis of various subsets of acute lymphoblastic leukemia. Haematol Blood Transfus. 1983; 28:146-7.
|
|
|
|
|
135.
|
Polliack A, Leizerowitz R, Korkesh A, Gurfel D, Gamliel H, Galili U. Exposure to phorbol diester (TPA) in vitro as an aid in the classification of blasts in human myelogenous and lymphoid leukemias: in vitro differentiation, growth patterns, and ultrastructural observations. Am J Hematol. 1982 Nov; 13(3):199-211.
|
|
|
|
|
136.
|
Mayer M, Galili U, Kaiser N. Intracellular protease activity in glucocorticoid-mediated thymolysis. Endocrinology. 1982 Jun; 110(6):2131-7.
|
|
|
|
|
137.
|
Galili U, Leizerowitz R, Moreb J, Gamliel H, Gurfel D, Polliack A. Metabolic and ultrastructural aspects of the in vitro lysis of chronic lymphocytic leukemia cells by glucocorticoids. Cancer Res. 1982 Apr; 42(4):1433-40.
|
|
|
|
|
138.
|
Cividalli G, Yatziv S, Voss R, Galili U, Kopolovic J, Sagi M, Weizman Z, Brautbar C, Kohn G. XX/XY lymphoid chimerism in a boy with fatal lymphohistiocytic proliferation. JAMA. 1981 Oct 23-30; 246(17):1917-20.
|
|
|
|
|
139.
|
Galili U, Rosenthal L, Klein E. Activated T cells in the synovial fluid of arthritic patients. II. In vitro activation of the autologous blood lymphocytes. J Immunol. 1981 Aug; 127(2):430-2.
|
|
|
|
|
140.
|
Galili U, Galili N, Or R, Polliack A. Analysis of the peanut agglutinin-binding site as a differentiation marker of normal and malignant human lymphoid cells. Clin Exp Immunol. 1981 Feb; 43(2):311-8.
|
|
|
|
|
141.
|
Galili U, Manny N, Izak G. EA rosette formation: a simple means to increase sensitivity of the antiglobulin test in patients with anti red cell antibodies. Br J Haematol. 1981 Feb; 47(2):227-33.
|
|
|
|
|
142.
|
Galili U, Prokocimer M, Izak G. The in vitro sensitivity of leukemic and normal leukocytes to hydrocortisone induced cytolysis. Blood. 1980 Dec; 56(6):1077-81.
|
|
|
|
|
143.
|
Galili U, Polliack A, Okon E, Leizerovitz R, Gamliel H, Korkesh A, Schenkar JG, Izak G. Human prothymocytes. Membrane properties, differentiation patterns, glucocorticoid sensitivity, and ultrastructural features. J Exp Med. 1980 Oct 1; 152(4):796-807.
|
|
|
|
|
144.
|
Galili U, Klein E, Christensson B, Biberfeld P. Lymphocytes of Hodgkin's biopsies exhibit: stable E-rosette formation, natural attachment and glucocorticoid sensitivity, similar to immunoactivated T cells. Clin Immunol Immunopathol. 1980 Jun; 16(2):173-9.
|
|
|
|
|
145.
|
Galili U, Seeley J, Svedmyr E, Klein E, Klein G, Weiland O. Blood lymphocytes in infectious mononucleosis share the following characteristics with activated T cells: natural attachment, stable E rosetting and glucocorticoid sensitivity. J Clin Lab Immunol. 1980 May; 3(3):153-8.
|
|
|
|
|
146.
|
Galili N, Galili U, Klein E, Rosenthal L, Nordenskjöld B. Human T lymphocytes become glucocorticoid-sensitive upon immune activation. Cell Immunol. 1980 Mar 15; 50(2):440-4.
|
|
|
|
|
147.
|
Galili U, Klein E, Klein G, Singh Bal I. Activated T lymphocytes in infiltrates and draining lymph nodes of nasopharyngeal carcinoma. Int J Cancer. 1980 Jan 15; 25(1):85-9.
|
|
|
|
|
148.
|
Klein E, Vánky F, Galili U, Vose BM, Fopp M. Separation and characteristics of tumor-infiltrating lymphocytes in man. Contemp Top Immunobiol. 1980; 10:79-107.
|
|
|
|
|
149.
|
Galili U, Klein E, Klein G, Biberfeld P. The natural attachment of thymocytes and activated T lymphocytes to normal and malignant cells: an interspecies study. Dev Comp Immunol. 1980; 4(2):367-73.
|
|
|
|
|
150.
|
Galili U, Häyry P, Klein E. Loss of net negative surface charge during MLC stimulation of human T lymphocytes: correlation to "stable" E-rosette formation and natural attachment to normal and malignant target cells. Cell Immunol. 1979 Nov; 48(1):91-9.
|
|
|
|
|
151.
|
Galili U, Rosenthal L, Galili N, Klein E. Activated T cells in the synovial fluid of arthritic patients: characterization and comparison with in vitro activated human and murine T cells in cooperation with monocytes in cytotoxicity. J Immunol. 1979 Mar; 122(3):878-83.
|
|
|
|
|
152.
|
Galili U, Galili N, Vánky F, Klein E. Natural species-restricted attachment of human and murine T lymphocytes to various cells. Proc Natl Acad Sci U S A. 1978 May; 75(5):2396-400.
|
|
|
|
|
153.
|
Galili U, Caine M, Servadio C, Schlesinger M. Specific attachment of T-lymphocytes from cancer patients to tumor cells. Cancer Lett. 1977 Sep; 3(3-4):121-4.
|
|
|
|
|
154.
|
Galili U, Brautbar C, Schlesinger M. Association between HLA determinants and complement receptors on human lymphocytes. Tissue Antigens. 1977 Aug; 10(2):99-107.
|
|
|
|
|
155.
|
Galili U, Klein E, Schlesinger M. Human T lymphocyte receptors for sheep red blood cells and specific antigens: are they identical sites on the cell membrane? J Immunol. 1977 Jul; 119(1):104-9.
|
|
|
|
|
156.
|
Ben-Zwi A, Galili U, Russell A, Schlesinger M. Age-associated changes in subpopulations of human lymphocytes. Clin Immunol Immunopathol. 1977 Jan; 7(1):139-49.
|
|
|
|
|
157.
|
Galili U, Schlesinger M. The formation of stable E-rosettes by human T lymphocytes activated in mixed lymphocyte reactions. J Immunol. 1976 Sep; 117(3):730-5.
|
|
|
|
|
158.
|
Raben M, Walach N, Galili U, Schlesinger M. The effect of radiation therapy on lymphocyte subpopulations in cancer patients. Cancer. 1976 Mar; 37(3):1417-21.
|
|
|
|
|
159.
|
Galili U, Schlesinger M. Proceedings: Delineation of distinct subpopulations of human thymus cells. Isr J Med Sci. 1975 Dec; 11(12):1380-1.
|
|
|
|
|
160.
|
Galili U, Schlesinger M. Studies on the formation of E-rosettes by human T lymphocytes and thymus cells. Effects of temperature, metabolic inhibitors and anti-T sera. Isr J Med Sci. 1975 Dec; 11(12):1357-67.
|
|
|
|
|
161.
|
Galili U, Eliakim M, Slavin S, Schlesinger M. Lymphocyte subpopulations in chronic active hepatitis: increase in lymphocytes forming stable E-rosettes. Clin Immunol Immunopathol. 1975 Nov; 4(4):538-44.
|
|
|
|
|
162.
|
Galili U, Schlesinger M. Subpopulations of human thymus cells differing in their capacity to form stable E-rosettes and in their immunologic reactivity. J Immunol. 1975 Sep; 115(3):827-33.
|
|
|
|
|
163.
|
Schlesinger M, Galili U. Antigenic differences between T and B lymphocytes in man. Isr J Med Sci. 1974 Jul; 10(7):715-24.
|
|
|
|
|
164.
|
Galili U, Schlesinger M. The formation of stable E rosettes after neuraminidase treatment of either human peripheral blood lymphocytes or of sheep red blood cells. J Immunol. 1974 May; 112(5):1628-34.
|
|
|
|
